News – Page 1144 – Endpoints News

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

9 years ago

Biogen spells out remarkable efficacy data in Alzheimer's for aducanumab, but safety threat persists

9 years ago

Virtual biotech star Mark de Souza signs up to help lead the team on a new co launch; Takeda partners with RNA ...

9 years ago

The 21st Century Cures Act is here to stay. Now what?

9 years ago

Gilead offers rare apology to payers over the hep C drug sticker shock

9 years ago

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

9 years ago

MPM kicks off a new I/O player with $44.5M round and a new understanding of the T cell receptor

9 years ago

Seasteader, drug libertarian and now FDA Commissioner? Peter Thiel backs a radical shift

9 years ago

Voyager shares spike on an early glimpse of promise for Parkinson’s gene therapy

9 years ago

Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout

9 years ago

J&J is forced to suspend recruitment in PhI diabetes study, raising questions about another Hanmi drug

9 years ago

AbbVie’s PARP inhibitor flounders in PhII as rivals surge ahead in late-stage drive

9 years ago

PEOTUS Donald Trump vows to rein in drug prices, slamming biotech stocks

9 years ago

Sayonara Novartis: Ex-cell therapy chief challenges CAR-T leaders, moves to Carl June’s biotech startup

9 years ago

With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug

9 years ago

Gladstone spinout Tenaya tackles new cures for heart failure with $50M A round

9 years ago

Is the US biopharma industry headed for a turning point in 2017?

9 years ago

GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid?

9 years ago

The FDA just signed off on a Formula 1 pivotal track for Sage's postpartum depression drug

9 years ago

In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII

9 years ago

Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017

9 years ago

Section 32: Ex-Google venture chief Maris pursues indie role with $230M biotech fund

9 years ago

Sarepta critic Jenkins is exiting the FDA, and Woodcock takes direct charge of the OND after a painful rupture

9 years ago

Merck is hiring as it shows off new Bay Area campus plans; Lilly, though, is reportedly laying off sales staff

9 years ago

First page Previous page 1141 1142 114311441145 1146 1147 Next page Last page